<code id='7D041715BF'></code><style id='7D041715BF'></style>
    • <acronym id='7D041715BF'></acronym>
      <center id='7D041715BF'><center id='7D041715BF'><tfoot id='7D041715BF'></tfoot></center><abbr id='7D041715BF'><dir id='7D041715BF'><tfoot id='7D041715BF'></tfoot><noframes id='7D041715BF'>

    • <optgroup id='7D041715BF'><strike id='7D041715BF'><sup id='7D041715BF'></sup></strike><code id='7D041715BF'></code></optgroup>
        1. <b id='7D041715BF'><label id='7D041715BF'><select id='7D041715BF'><dt id='7D041715BF'><span id='7D041715BF'></span></dt></select></label></b><u id='7D041715BF'></u>
          <i id='7D041715BF'><strike id='7D041715BF'><tt id='7D041715BF'><pre id='7D041715BF'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:423
          Adobe

          An advisory panel to the Food and Drug Administration delivered a split decision on a surgical system used in a controversial blood pressure treatment called renal denervation. 

          The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.

          advertisement

          “While this is a very safe procedure, the efficacy was mild at best,” Keith Allen, director of surgical research at St. Luke’s Hospital of Kansas City, said regarding Medtronic’s device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Why Novartis is changing the name of its research labs
          Why Novartis is changing the name of its research labs

          FionaMarshall,presidentoftheNovartisresearchhubinCambridge,Mass.,speaksThursdayduringtheSTATFutureSu

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Listen: Biogen's potential pivot, & Illumina's next chapter

          Aretherestilltoomanybiotechcompanies?Howdoyouknowwhenyou’reinabubble?Andisthereawrongwaytopronounce“